Research

UK’s Sanders-Brown Center on Aging Receives $14.5 Million to Continue Alzheimer’s Disease Research and Outreach

of
Mark Ebbert, Ph.D., is a member of the UK Sanders-Brown Center on Aging research team. UK Photo l Pete Comparoni

LEXINGTON, Ky. (Aug. 18, 2021) — The University of Kentucky Sanders-Brown Center on Aging (SBCoA) has received $14.5 million in renewed funding for its Alzheimer’s Disease Research Center (ADRC) program from the National Institute on Aging (NIA), a division of the National Institutes of Health (NIH).

The five-year award will allow UK to remain among the leaders in Alzheimer’s disease research and associated neurodegenerative disorders. It will support research, teaching, outreach and service activities and a multidisciplinary team involving 26 faculty members from 14 academic departments, and 29 postdoctoral and staff members.

“As global experts in their field, our researchers at the Sanders-Brown Center on Aging are dedicated to discovering solutions to one of our society’s greatest medical challenges,” said UK President Eli Capilouto. “The continuous federal funding received by the center is a result of a legacy of aging and Alzheimer’s research that has been conducted here in Lexington — and recognized around the world — for more than 35 years.”

The UK-ADRC is part of a national network of federally funded and designated research programs based in academic medical settings. Initially funded in 1985, UK was one of the original 10 ADRCs in the United States. The ultimate goal of the UK-ADRC is to catalyze pioneering basic, translational and clinical research in Alzheimer’s disease and related dementias while ensuring a more rapid rate of progress toward new therapies so that volunteers and their families become the beneficiaries of advances in knowledge.

“For over three decades, Sanders-Brown Center on Aging has been home to one of the premier research institutions in our country in the fight to defeat Alzheimer's and other dementias," said U.S. Rep. Andy Barr. "I am proud to champion federal funding in support of the extraordinary work being done at UK’s Sanders-Brown Center on Aging and I look forward to supporting Sanders-Brown and their mission in the future.” 

The grant will provide funding for the ADRC’s six signature Cores (Administrative, Clinical, Neuropathology, Biomarker, Data Management & Statistics, and Outreach, Recruitment & Engagement), six developmental pilot projects and five junior scholar training positions over the five-year funding period under the direction of Linda J. Van Eldik, Ph.D., director of the UK Sanders-Brown Center on Aging, co-director of the Kentucky Neuroscience Institute. The upcoming funding cycle represents years 36 to 40 of continuous funding of the ADRC.

“The UK-ADRC provides the resources and interactive environment to support and create new opportunities for groundbreaking research discoveries,” said Van Eldik, who is also professor of neuroscience in the UK College of Medicine and holds the Dr. E. Vernon Smith and Eloise C. Smith Alzheimer's Research Endowed Chair. “Major areas of research emphasis in the center include efforts to identify the earliest changes in the brain and mechanisms behind the transitions from healthy brain aging to the development of cognitive impairment, to understand how multiple changes in the brain influence risk of memory problems, and what we can do to maintain a healthy brain as we age.”

In addition to research, the UK-ADRC is also dedicated to growing education and outreach programs, family support and community partnerships to promote awareness of the center and the resources and services provided.

“This grant has far-reaching effects,” said Lisa Cassis, Ph.D., UK vice president for research. “In addition to supporting the six cores of the ADRC here at UK, the funding allows Sanders-Brown researchers to collaborate on studies with other research centers, to share research data as part of a national coordinating center, to make experimental drugs available to patients through national clinical trials and to bring in additional NIH funds for research projects.”

Over the last five years, some of what the UK-ADRC has achieved includes:

  • Supported 114 federally funded research grants and 31 nonfederal funding awards.
  • Supported 204 direct and 86 indirect publications that have contributed substantially to a better understanding of basic and clinical aspects of Alzheimer’s and related diseases.
  • Leveraged resources to fund 17 pilot projects testing novel research ideas. The 14 completed projects generated 33 publications and 10 successful grants. This extramural funding from NIH represents an outstanding >23-fold return on investment.
  • Supported 42 clinical trials testing potential new medicines or lifestyle interventions.
  • Supported 19 training or fellowship awards; 202 collaborative studies with institutions, industry, ADRC cooperatives and other collaborators; and five grants related to underrepresented groups.
  • Provided extensive Neuropathology Tissue Bank specimens. The Neuropathology Core provided a total of 18,458 biosamples to laboratories around the world.
  • Achieved successful minority recruitment and outreach and new community partnerships.
  • Recruited and onboarded 15 new translational/clinical faculty into the SBCoA since 2010 with all conducting impactful research relevant to UK-ADRC goals. These recruitments join a cadre of other outstanding investigators in the SBCoA, supported by UK-ADRC resources, who are doing cutting-edge research in healthy brain aging and dementia.

“These achievements have been made possible by our longstanding cohort of highly dedicated community volunteers who agree to annual evaluations and brain donation after death,” said Van Eldik. “We are so grateful for their participation because it is enabling us to develop new biomarkers for early diagnosis, define risk factors that can either increase or reduce risk of memory impairment and identify potential new therapies or effective interventions.”

The continuously replenished longitudinal cohort, which is a type of research study that follows large groups of people over an extended time, was established in 1989. The cohort consists of about 500 cognitively normal volunteers and about 200 additional individuals who transitioned to mild cognitive impairment or dementia.

“As Kentuckians, we should be proud of the fact that the Bluegrass is home to many of the leading researchers and physicians found anywhere in the country thanks to the UK Sanders-Brown Center on Aging,” said Mark F. Newman, M.D., UK executive vice president for health affairs. “The work being done by this research team and this center is another significant way that UK is focused on solving the health problems of Kentuckians and beyond.”

The University of Kentucky is increasingly the first choice for students, faculty and staff to pursue their passions and their professional goals. In the last two years, Forbes has named UK among the best employers for diversity, and INSIGHT into Diversity recognized us as a Diversity Champion four years running. UK is ranked among the top 30 campuses in the nation for LGBTQ* inclusion and safety. UK has been judged a “Great College to Work for" three years in a row, and UK is among only 22 universities in the country on Forbes' list of "America's Best Employers."  We are ranked among the top 10 percent of public institutions for research expenditures — a tangible symbol of our breadth and depth as a university focused on discovery that changes lives and communities. And our patients know and appreciate the fact that UK HealthCare has been named the state’s top hospital for five straight years. Accolades and honors are great. But they are more important for what they represent: the idea that creating a community of belonging and commitment to excellence is how we honor our mission to be not simply the University of Kentucky, but the University for Kentucky.